CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		204 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Cash Flows From Operating Activities:
Net income/(loss)	$ (656,199)	$ 336,354	$ (354,829,759)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Depreciation and amortization	117,027	163,703	10,025,567
Minority Interest Share of Loss	0	0	(3,038,185)
Reduction of notes receivable - common stock in exchange for services rendered	0	0	423,882
Write-off of uncollectible notes receivable - common stock	0	0	391,103
Write-off of deferred offering costs	0	0	3,406,196
Write-off of abandoned patents	0	88,582	1,353,976
(Gain)/Loss on disposal of property and equipment	(994,125)	(639,680)	(2,985,275)
Loss on extinguishment of debt	0	0	14,134,068
Common stock issued as employee compensation	0	11,783	4,011,938
Amortization of options and option modifications as stock compensation	9,993	22,690	3,421,219
Common stock issued for services rendered	114,250	48,195	14,621,529
Amortization of prepaid services in conjunction with common stock issuance	0	0	138,375
Non-cash compensation expense	0	0	45,390
Stock options and warrants issued for services rendered	0	0	7,956,723
Issuance of warrants as additional exercise right inducement	0	0	21,437,909
Preferred stock issued for services rendered	0	0	100
Treasury stock redeemed for non-performance of services	0	0	(138,000)
Amortization of deferred debt issuance costs and loan origination fees	0	0	2,405,629
Amortization of discount on convertible debentures	0	0	38,345,592
Common stock issued for interest on convertible debentures & preferred stock	188,514	212,490	1,431,218
Interest on short-term advance	0	0	22,190
Founders' shares transferred for services rendered	0	0	353,506
Fees in connection with refinancing of debt	0	0	113,274
Warrant repricing costs	0	0	3,198,604
Change in fair value of derivative liabilities	(358,714)	(3,128,459)	357,263	[1]
Changes in operating assets and liabilities (excluding the effects of acquisition):
Accounts receivable	0	6,774	(15,047)
Miscellaneous receivables	0	0	43,812
Inventory	0	216,011	(20,091)
Other current assets	85,452	28,949	(97,496)
Accounts payable and accrued expenses	559,973	(13,908)	15,583,913
Deferred revenue	(20,769)	(6,471)	236,563
Other, net	0	0	110,317
Net Cash Used in Operating Activities	(954,598)	(2,652,987)	(217,553,996)
Cash Flows From Investing Activities:
Purchase of property and equipment	0	(2,416)	(4,809,439)
Proceeds from sale of property and equipment	1,579,189	1,669,115	6,532,514
Costs incurred for patents	(23,475)	(39,621)	(2,863,521)
Change in restricted cash	0	0	512,539
Proceeds from maturity of short term investments	0	0	195,242,918
Purchases of short-term investments	0	0	(195,242,918)
Cash received in conjunction with merger	0	0	82,232
Advances to Antigen Express, Inc.	0	0	(32,000)
Increase in officers' loans receivable	0	0	(1,126,157)
Change in deposits	0	0	(652,071)
Change in notes receivable - common stock	0	0	(91,103)
Change in due from related parties	0	0	(2,222,390)
Other, net	0	0	89,683
Net Cash Provided by/(Used in) Investing Activities	1,555,714	1,627,078	(4,579,713)
Cash Flows From Financing Activities:
Proceeds from short-term advance	0	0	325,179
Repayment of short-term advance	0	0	(347,369)
Proceeds from issuance of long-term debt	0	0	5,567,297
Repayment of long-term debt	(1,534,577)	(684,673)	(8,597,276)
Repayment of obligations under capital lease	0	0	(83,002)
Change in due to related parties	0	0	154,541
Proceeds from exercise of warrants	0	0	45,728,281
Proceeds from exercise of stock options	0	0	5,003,793
Proceeds from minority interest investment	0	0	3,038,185
Proceeds from issuance of preferred stock	725,000	0	17,030,000
Redemption of SVR preferred stock	0	0	(100)
Proceeds from issuance of convertible debentures, net	0	0	40,704,930
Payment of costs associated with convertible debentures	0	0	(722,750)
Repayments of convertible debentures	0	0	(5,142,424)
Purchase of treasury stock	0	0	(483,869)
Proceeds from issuance of common stock, net	0	0	120,576,242
Purchase and retirement of common stock	0	0	(497,522)
Net Cash (Used in)/Provided by Financing Activities	(809,577)	(684,673)	222,254,136
Effect of Exchange Rates on Cash	(817)	(18,712)	(83,396)
Net (Decrease)/Increase in Cash and Cash Equivalents	(209,278)	(1,729,294)	37,031
Cash and Cash Equivalents, Beginning of Period	246,309	2,798,797
Cash and Cash Equivalents, End of Period	37,031	1,069,503	37,031
Supplemental Cash Flow Information [Abstract]
Interest	117,975	34,921
Income taxes	$ 0	$ 0

[1] includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to October 31, 2012" column. See Note 10 - Derivative Liabilities.